Ambu A/S (AMBU B.CO) Stock Price
Ambu A/S Price
Over the last 19 years Ambu A/S grew revenue by 11.9% annually, reaching 6.04 B DKK. Earnings per share have grown at 14.2% per year over the last 19 years. For Ambu A/S, the net margin of 10.1% is up versus 6.2% a few years ago. At today's price the dividend yield works out to roughly 0.56%. The payout ratio is around 18% of earnings. The dividend has grown at 6.5% per year over the past 19 years. The consensus 12-month price target for Ambu A/S is 122.40 DKK, about 68.0% above where the stock trades today. Of 12 analysts, 9 rate the stock a buy — an overall Buy consensus.
Ambu A/S stock price
Ambu A/S business model & stock analysis
Frequently asked questions about Ambu A/S
Ambu A/S is primarily present in various countries and regions worldwide. With its global presence, Ambu A/S operates in several key markets, including Europe, North America, and Asia-Pacific. The company's products and services cater to customers across numerous geographies, facilitating access to innovative medical solutions. Ambu A/S leverages its extensive international network to deliver high-quality healthcare devices and support healthcare professionals in improving patient outcomes. With a strong presence in multiple countries and regions, Ambu A/S demonstrates its commitment to serving customers and driving advancements in medical technology on a global scale.
Ambu A/S is a Danish company specializing in the development, manufacturing, and marketing of medical devices. Its business model revolves around providing innovative solutions for healthcare professionals, with a focus on respiratory care and patient monitoring. Ambu offers a wide range of high-quality products, such as flexible endoscopes, anesthesia devices, and single-use consumables. By combining expertise in engineering, medical science, and digital technology, Ambu aims to improve patient care, enhance clinical efficiency, and reduce healthcare costs. With a commitment to continuous research and development, Ambu strives to provide medical professionals with state-of-the-art solutions that prioritize patient safety and comfort.
Ambu A/S is primarily active in the medical device industry.
The main competitors of Ambu A/S in the market include Medtronic, Philips Healthcare, and Smiths Medical.
Ambu A/S is a Danish company specializing in medical devices and equipment. Established in 1937, Ambu has a rich history and a strong background in the healthcare industry. The company's focus lies in developing innovative solutions for diagnostics and patient monitoring, including products such as endoscopes and anesthesia masks. Ambu has a global presence, with operations in more than 120 countries and partnerships with various healthcare providers. Over the years, Ambu has earned a reputation for its high-quality products and commitment to improving patient care. With its extensive experience and expertise, Ambu A/S continues to be a leading player in the medical technology sector.
Some significant milestones achieved by Ambu A/S include continuous innovation in the field of single-use endoscopy, leading to the development of Ambu® aScope™, an innovative solution for visualizing the airways. The company has also achieved global recognition for their breakthrough product, Ambu® BlueSensor™ electrodes, which are used in monitoring patient vital signs during surgery. Ambu A/S has expanded its presence across multiple countries, establishing a strong global footprint. Moreover, the company has received several prestigious awards, including the Red Dot Design Award and the Medical Design Excellence Award, affirming their commitment to providing high-quality medical devices.
Ambu A/S represents a corporate philosophy based on certain key values. These values include innovation, quality, and a focus on improving patient outcomes. Ambu aims to provide innovative medical solutions that enhance the efficiency and safety of medical procedures. The company strives to maintain a high standard of quality in its product offerings, ensuring reliability and accuracy for healthcare professionals. Ambu's mission is to enable medical professionals to make better decisions and improve patient care. With a commitment to these values, Ambu A/S aims to be a trusted leader in the medical device industry.
Analysts currently set an average price target of 121.52 DKK for the Ambu A/S stock (median: 122.40 DKK), implying +66.8 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Ambu A/S stock: 9 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Ambu A/S to generate revenue of 6.44 B DKK and earnings per share of 2.10 DKK.
Converted at the current exchange rate, the Ambu A/S share trades at 9.75 EUR (72.85 DKK).
The Ambu A/S share (AMBU B.CO) is listed on 7 stock exchanges, including: London (0MJF.L), Frankfurt (547A.F), München (547A.MU), Düsseldorf (547A.DU), Kopenhagen (AMBU-B.CO).
Ambu A/S is a Danish company specializing in the development, production, and marketing of medical products. It was founded in 1937 and is headquartered in Copenhagen. The company has branches in various parts of the world. Ambu is focused on three main business areas: anesthesia, patient monitoring, and diagnostics. In the anesthesia field, Ambu offers devices and instruments used in anesthesia procedures, including laryngeal tubes, masks, and ventilator bags. In patient monitoring, Ambu provides a range of products, including electrodes for measuring brain activity, accessories for EKG and pulse oximetry, and non-invasive blood pressure monitors. In the diagnostics field, Ambu offers endoscopes used in the examination of body cavities and internal organs. The company follows a business model focused on innovation and technological advancement. It invests a significant portion of its revenue in research and development to bring new and improved products to the market that meet customer requirements and contribute to improving medical care. Ambu also emphasizes high product quality and safety throughout the value chain, from development and production to marketing and customer support. In addition to product sales, Ambu provides comprehensive support and training opportunities to its customers, building strong long-term relationships. Overall, Ambu is a leading company in the field of medical technology, dedicated to improving medical care through innovative and effective products.
The expected revenue of Ambu A/S is 6.44 B DKK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Ambu A/S is 562.73 M DKK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Ambu A/S is currently 34.72. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ambu A/S stock.
The price-to-sales ratio (P/S) of Ambu A/S is currently 3.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ambu A/S stock.
The Eulerpool Quality Score for Ambu A/S is 7/10.
The ISIN of Ambu A/S is DK0060946788. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Ambu A/S is A2JAHY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Ambu A/S is AMBU B.CO. The ticker symbol is used to trade Ambu A/S shares on the stock exchange.
Ambu A/S stock
All fundamentals and in-depth analysis of Ambu A/S
Our stock analysis for Ambu A/S stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ambu A/S. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.